These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

397 related items for PubMed ID: 11078282

  • 1. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    Boden WE, Pearson TA.
    Am J Cardiol; 2000 Mar 01; 85(5):645-50, A10. PubMed ID: 11078282
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
    Sprecher DL.
    Am J Cardiol; 2000 Dec 21; 86(12A):46L-50L. PubMed ID: 11374856
    [Abstract] [Full Text] [Related]

  • 6. Niacin as a component of combination therapy for dyslipidemia.
    Miller M.
    Mayo Clin Proc; 2003 Jun 21; 78(6):735-42. PubMed ID: 12934785
    [Abstract] [Full Text] [Related]

  • 7. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG, Ibrahim M.
    J Clin Hypertens (Greenwich); 2006 Jul 21; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE.
    Curr Opin Cardiol; 2003 Jul 21; 18(4):278-85. PubMed ID: 12858126
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
    Bloomgarden ZT.
    Diabetes Care; 2005 Nov 21; 28(11):2795-802. PubMed ID: 16249560
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 21; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
    Boden WE.
    Am J Cardiol; 2000 Dec 21; 86(12A):19L-22L. PubMed ID: 11374850
    [Abstract] [Full Text] [Related]

  • 16. Beyond LDL-C--the importance of raising HDL-C.
    Wierzbicki AS, Mikhailidis DP.
    Curr Med Res Opin; 2002 Dec 21; 18(1):36-44. PubMed ID: 11999145
    [Abstract] [Full Text] [Related]

  • 17. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF.
    Am J Cardiol; 2011 Mar 15; 107(6):886-90. PubMed ID: 21247526
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treating mixed dyslipidemias: why and how.
    Ballantyne CM.
    Clin Cardiol; 2001 Mar 15; 24(7 Suppl):II-6-9. PubMed ID: 11444652
    [Abstract] [Full Text] [Related]

  • 20. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials.
    Sacks FM.
    Am J Cardiol; 2001 Dec 20; 88(12A):14N-18N. PubMed ID: 11788125
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.